Genzyme has just revealed that it found an impurity in a single vial of its Gaucher's disease drug Cerezyme (imiglucerase) from its fill-finish facility in Waterford, Ireland last December.
However, it downplayed the problem, noting that the ...
IMS Health is predicting that emerging markets will expand by $90 billion during 2009-13, contributing 48% of annual pharmaceutical market growth in 2013, a jump from 37% in 2009.
This comes at time when many multinational pharma firms are looking ...
Promedior has raised $12 million in a series C financing round. The clinical-stage US biotechnology company is developing therapies to treat inflammatory and fibrotic diseases. Forbion Capital Partners , the only new investor, led the round with ...
Pharming 's shares have fallen by 12% on news that the Dutch firm is planning a share issue. The company will hold an extraordinary general meeting (EGM) where it will ask shareholders to approve plans to raise more cash.
Pharming ended 2009 with ...
The privately owned French biotech firm Bioprojet says that its new compound for excessive daytime sleepiness (EDS), pitolisant, has shown good results in several European Phase II trials and has now begun Phase III development.
The product, which ...
